This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hultman, M. L. Articles by Hu, X. Search for Related Content PubMed PubMed Citation Articles by Hultman, M. L. Articles by Hu, X.

The Ligand-Dependent Interaction of Mineralocorticoid Receptor with Coactivator and Corepressor Peptides Suggests Multiple Activation Mechanisms

St. Louis Laboratories, Biological Sciences, Pfizer Global Research & Development, St. Louis, Missouri 63017

Address all correspondence and requests for reprints to: Xiao Hu, Ph.D, Mail Zone AA3G, Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017. E-mail: Xiao.Hu{at}pfizer.com.

We investigated the coregulator (coactivator and corepressor) interactions with the mineralocorticoid receptor (MR) that lead to activation and inhibition of the receptor in the presence of agonist and/or antagonist. Our results indicate that MR ligand binding domain (LBD) interacts strongly with only a few specific coactivator peptides in the presence of the agonist aldosterone and that these interactions are blocked by the antagonist eplerenone. We also discovered that cortisol, the preferred physiological ligand for the glucocorticoid receptor in humans, is a partial MR agonist/antagonist, providing a possible molecular explanation of the tissue-selective effects of glucocorticoids on MR. However, when we examined the coactivator and corepressor peptide interactions in the presence of cortisol, we found that MR bound with cortisol or aldosterone interacted with the same set of peptides. Thus, the partial agonism shown by cortisol is unlikely to be the result of differential interaction with known coactivators and corepressors. On the other hand, we have identified coactivator binding groove mutations that are critical for cortisol activation but not for aldosterone activation, suggesting that the two steroids induce different MR LBD conformations. In addition, we also show that cortisol becomes full agonist when S810L mutation is introduced in the LBD of MR. Interestingly, MR antagonists, such as eplerenone and progesterone, become partial agonist/antagonist of S810L but are still able to recruit LXXLL peptides to the mutant receptor. Together, these findings suggest a model to explain the MR activation by various ligands.

NURSA Molecule Pages Link:

Nuclear Receptors:   MR

Coregulators:   RIP140  |  NSD1  |  TRAP220  |  PGC-1  |  p120  |  TIF1α  |  LCoR  |  PRIC285  |  PGC-1β  |  NIX1  |  CBP  |  p300  |  Tip60  |  SRC-1  |  GRIP1  |  AIB1  |  ARA70  |  CIA  |  ASC-2  |  ERAP140  |  NCOR  |  SMRT

Ligands:   Dexamethasone  |  Hydrocortisone  |  Aldosterone  |  Progesterone  |  RU486

This article has been cited by other articles:

				J. Yang and M. J Young The mineralocorticoid receptor and its coregulators J. Mol. Endocrinol., August 1, 2009; 43(2): 53 - 64. [Abstract] [Full Text] [PDF]

				E. P. Gomez-Sanchez, M. T. Gomez-Sanchez, A. F. de Rodriguez, D. G. Romero, M. P. Warden, M. W. Plonczynski, and C. E. Gomez-Sanchez Immunohistochemical Demonstration of the Mineralocorticoid Receptor, 11{beta}-Hydroxysteroid Dehydrogenase-1 and -2, and Hexose-6-phosphate Dehydrogenase in Rat Ovary J. Histochem. Cytochem., July 1, 2009; 57(7): 633 - 641. [Abstract] [Full Text] [PDF]

				T. Wada, S. Ohshima, E. Fujisawa, D. Koya, H. Tsuneki, and T. Sasaoka Aldosterone Inhibits Insulin-Induced Glucose Uptake by Degradation of Insulin Receptor Substrate (IRS) 1 and IRS2 via a Reactive Oxygen Species-Mediated Pathway in 3T3-L1 Adipocytes Endocrinology, April 1, 2009; 150(4): 1662 - 1669. [Abstract] [Full Text] [PDF]

				J. B Pippal and P. J Fuller Structure-function relationships in the mineralocorticoid receptor J. Mol. Endocrinol., December 1, 2008; 41(6): 405 - 413. [Abstract] [Full Text] [PDF]

				K. Suino-Powell, Y. Xu, C. Zhang, Y.-g. Tao, W. D. Tolbert, S. S. Simons Jr., and H. E. Xu Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol Mol. Cell. Biol., March 15, 2008; 28(6): 1915 - 1923. [Abstract] [Full Text] [PDF]

				J. D. Dietz, S. Du, C. W. Bolten, M. A. Payne, C. Xia, J. R. Blinn, J. W. Funder, and X. Hu A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity Hypertension, March 1, 2008; 51(3): 742 - 748. [Abstract] [Full Text] [PDF]

				J. Huyet, G. M. Pinon, M. R. Fay, J. Fagart, and M.-E. Rafestin-Oblin Structural Basis of Spirolactone Recognition by the Mineralocorticoid Receptor Mol. Pharmacol., September 1, 2007; 72(3): 563 - 571. [Abstract] [Full Text] [PDF]

				K. Yokota, H. Shibata, I. Kurihara, S. Kobayashi, N. Suda, A. Murai-Takeda, I. Saito, H. Kitagawa, S. Kato, T. Saruta, et al. Coactivation of the N-terminal Transactivation of Mineralocorticoid Receptor by Ubc9 J. Biol. Chem., January 19, 2007; 282(3): 1998 - 2010. [Abstract] [Full Text] [PDF]

				X. Hu and J. W. Funder The Evolution of Mineralocorticoid Receptors Mol. Endocrinol., July 1, 2006; 20(7): 1471 - 1478. [Abstract] [Full Text] [PDF]

				P. J. Fuller and M. J. Young Mechanisms of Mineralocorticoid Action Hypertension, December 1, 2005; 46(6): 1227 - 1235. [Abstract] [Full Text] [PDF]